The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
Meissner
H Cody
HC
Division of Pediatric Infectious Disease, Tufts Medical Center, Boston, Massachusetts 02111, USA. cmeissner@tuftsmedicalcenter.org
Bocchini
Joseph A
JA
Brady
Michael T
MT
Hall
Caroline B
CB
Kimberlin
David W
DW
Pickering
Larry K
LK
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D019317:Evidence-Based Medicine; D017048:Health Care Costs / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D000069455:Palivizumab; D011159:Population Surveillance; D017410:Practice Guidelines as Topic; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis / Q000191:economics / Q000276:immunology* / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000187:drug effects* / Q000276:immunology*; D012307:Risk Factors; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab